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ABSTRACT
Introduction: Piperacillin/tazobactam is a
commonly used antibiotic for the empirical
treatment of severe diabetic foot infections.
One of the most feared complications of this
drug is the development of pancytopenia. The
aim of this study was to determine whether the
use of piperacillin/tazobactam caused any
hematological changes in patients admitted
with severe diabetes-related foot infections from
a specialist multidisciplinary foot clinic. Specif-
ically, looking at whether it caused anemia,
leukopenia, neutropenia, or thrombocytopenia.
Methods: A 1-year retrospective analysis of
patients admitted to a tertiary care center for
treatment of diabetes-related foot infection
using piperacillin/tazobactam. Hematological
indices, urea and electrolytes, and C-reactive
protein (CRP) were recorded pretreatment,
during treatment, and posttreatment. HbA1c,
vitamin B12, folate, thyroid-stimulating hor-
mone, and free thyroxin were also analyzed to
exclude any potential confounders as a cause of
pancytopenia.
Results: A total of 154 patients were admitted
between 1 January 2016 and 31 December 2016
who received piperacillin/tazobactam for severe
diabetes-related foot infection. On admission,
white cell count and CRP were raised and fell
significantly within the first 48 h. Other hema-
tological factors did not change. Five patients
developed a mild pancytopenia, of which three
were unexplained.
Conclusion: In this relatively small cohort,
pancytopenia did not occur. As such,
piperacillin/tazobactam appeared to have a low
risk of adverse hematological outcomes and
remains the treatment of choice for severe dia-
betes-related foot infections.
Keywords: Diabetic foot infection;
Piperacillin/tazobactam; Pancytopenia
INTRODUCTION
In 2015, worldwide, the prevalence of diabetes
in adults aged between 20 and 79 years old was
estimated at 415 million people, at an annual
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global cost of approximately US$1.3 trillion
[1, 2]. A significant part of this cost was due to
acute hospital admissions. Diabetic foot infec-
tions are common, and are the most common
reason for a ‘‘diabetes-specific’’ acute hospital
admission, accounting for the most hospital
days of all diabetes-related complications [3, 4].
Most moderate to severe diabetic foot infec-
tions are due to polymicrobial colonization of
tissue by Gram-positive cocci, aerobic Gram
negative bacilli, and anaerobes [5–7]. As such,
the empirical use of broad-spectrum antibiotics
prior to sensitivities being available have proved
to be clinically effective, with reported rates of
clinical resolution between 77% and 94%
[5, 8–10]. Piperacillin/tazobactam (Tazocin,
Pfizer Ltd, Sandwich, UK) is an antibiotic con-
taining the extended-spectrum agent piper-
acillin together with the b-lactamase inhibitor
tazobactam. The drug has activity against a wide
variety of Gram-positive and Gram-negative
organisms and Pseudomonas aeruginosa. Because
of its extended spectrum, the drug has been
shown to be effective in treating moderate to
severe diabetic foot infections [5–13], showing
an advantage over ertapenem [5]. Conse-
quently, piperacillin/tazobactam is commonly
recommended as first-line empirical treatment
owing to its high efficacy and relative safety
compared with other antibiotics [8, 12, 14–16].
The manufacturer’s package leaflet for
piperacillin/tazobactam [15] has documented
that pancytopenia is a side effect of the drug,
with the British National Formulary (BNF) also
stating this adverse drug reaction [17]. Evidence
from both sources imply that pancytopenia is
uncommon, with the manufacturer declaring
that the frequency cannot be determined from
the available data, and the BNF as ‘‘very rarely’’.
Case reports have also inferred the relation-
ship between piperacillin/tazobactam and
hematological changes, which is caused by
reversible bone marrow suppression. Several
case reports and cohort studies [18–25] as well
as a systematic review [26] have shown patients
to have neutropenia, leukopenia, agranulocy-
tosis, or pancytopenia associated with treat-
ment by piperacillin/tazobactam. However,
evidence suggests that this is dose and duration
dependent [25].
There is little evidence regarding hemato-
logical complications specifically in diabetic
foot infection patients receiving
piperacillin/tazobactam. The current literature
evidence consists of case reports [19]. A sys-
tematic review of piperacillin-induced neu-
tropenia found that whilst neutropenia was a
rare complication in patients receiving piper-
acillin for over 15 days, the authors could not
rule out hematological complications occurring
prior to 15 days and that this required further
investigation [26].
The significance of this adverse effect is
considerable because pancytopenia in diabetic
foot patients could worsen their infection and
increase patient mortality [27]. The threat of
pancytopenia could also act as a potential
deterrent for the routine use of
piperacillin/tazobactam.
The aim of this study is to assess whether
hematological changes/pancytopenia occurs in
patients with diabetic foot infections treated
with piperacillin/tazobactam and to evaluate
the appropriateness of this commonly used
antibiotic.
METHODS
This study was a 1-year retrospective analysis of
all patients admitted to the Norfolk and Nor-
wich University Hospitals NHS Foundation
Trust (Norwich, UK) between 1 January 2016
and 31 December 2016 for treatment of diabetic
foot infections treated with piperacillin/ta-
zobactam. This was a pragmatic study using a
convenience sample.
After completion of the intravenously
administered piperacillin/tazobactam course,
orally administered co-amoxiclav 625 mg three
times daily was prescribed to the majority of
patients, as per the local guidelines for diabetic
foot infections [14]. Once antimicrobial sensi-
tivities were known, the piperacillin/tazobac-
tam was changed to a variety of other
antibiotics. These included ciprofloxacin
500 mg twice daily; metronidazole 400 mg
three times daily; trimethoprim 200 mg twice
daily; vancomycin 1 g as a one-off dose and
then dosed according to plasma concentrations;
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doxycycline 200 mg once daily; gentamicin
dosed according to body weight and flu-
cloxacillin 500 mg four times daily.
All patients admitted with diabetic foot
infections are seen by the inpatient multidis-
ciplinary specialist diabetes foot team and
their details kept electronically. Medication
used was assessed using the E-Prescribing
Medicines Administration (EPMA) system (JAC
Medicines Management, Basildon, UK). Using
the date of admission, we interrogated EPMA
to identify patients receiving piperacillin/ta-
zobactam for their diabetes-related foot
infection; the date of administration and dose
were noted. Patients were also excluded if
they had no blood test results from the date of
piperacillin/tazobactam administration to
28 days post administration.
Blood test results were recorded from the
hospital’s central pathology system Sunquest
Integrated Clinical Environment (ICE) (Sun-
quest Information Systems, Uxbridge UK).
Pretreatment values (including single values
from any of the 3 days before administration),
those taken during piperacillin/tazobactam
administration (day 1–7), and posttreatment
values [14 days after day 7 (± 7 days)] were
recorded. This length of follow-up was chosen
because of previous data showing that the
medial length of stay using our previous pub-
lished antibiotic regimen was 9.25 days (IQR
2–25) [14]. In addition, glycated hemoglobin
(HbA1c), vitamin B12, folate, thyroid-stimulat-
ing hormone, and free thyroxin were also
recorded pre and post administration, in order
to exclude any potential confounders causing
pancytopenia.
The hospital electronic letters template was
also interrogated to check for potentially con-
founding causes of hematological
abnormalities.
This was a retrospective case notes analysis
study and as such the Norfolk and Norwich
University Hospitals NHS Foundations Trust
audit department designated this as a service
improvement exercise and ethical approval was
deemed unnecessary. This article is based on
previously conducted studies and does not
involve any new studies of human or animal
subjects performed by any of the authors.
RESULTS
The Consort diagram showing patient selection
is shown in Fig. 1. Of the 154 people included in
the analysis, only 38 were female. The cohort
had a mean age of 69 years (SD ± 14.46). Of
these 154 patients receiving piperacillin/ta-
zobactam, 131 patients received 4.5 g three
times daily while 22 patients received 4.5 g
twice daily, all via intravenous infusion. One
patient received a single dose only at the time of
admission. The mean duration of
piperacillin/tazobactam administration was
5.3 days (SD ± 3.3).
Data were collated giving the mean values at
each time point, standard deviations, and the
number of data points were calculated. These
Fig. 1 Consort diagram illustrating the study of patients
into the study
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data are presented in Table 1 and graphically in
the supplementary materials.
A non-specific marker of infection, CRP, was
used to indicate the progress of the patient’s
diabetic foot infection during piperacillin/ta-
zobactam treatment. Figure 2 shows an initial
rise in CRP 2 days after initiation of treatment.
This is followed by a fall, as well as improve-
ments in all of the other measured hematolog-
ical values over the remaining duration of
piperacillin/tazobactam administration and
follow-up (Table 1 or Supplementary Figs. A–E).
Hematological Parameters
The mean lymphocyte count dropped initially,
reaching a nadir after 48 h. It then rose reaching
a peak at 7 days. Basophil concentrations
remained low for the first 4 days after admission
before rising to a maximum by 7 days. Mono-
cyte concentrations remained broadly unchan-
ged from the time of admission for 48 h, and
then fell for a further 48 h before returning to
values similar to those on admission by 7 days.
Eosinophil concentrations dropped slightly in
the first 24 h following admission, but then
steadily rose to reach a maximum by 7 days. The
mean red blood cell count rose after the first
24 h admission and then fell to a nadir at 4 days
after admission before returning to values sim-
ilar to those on admission by 7 days. Mean
corpuscular hemoglobin rose to reach a maxi-
mum by 24 h and then fell to reach a nadir by
7 days. Values at 14 days were similar to those at
7 days. Mean corpuscular volume was generally
unchanged during the whole admission.
Hematological parameters were evaluated for
mean values outside of the reference range. For
the purposes of this study, mean values below
the lower limit of normal were evaluated to
assess for pancytopenia or individual abnor-
malities of that particular parameter. Results
above the upper limit of normal were to be
expected in a normal response to a bacterial
infection. Table 1 and Supplementary Figs. A–E
show that all values improved from the peak of
infection on day 2 to 14 days posttreatment,
with all of them being within the reference
ranges by 14 days. Most of these parameters also
remained within the reference range through-
out the study period, with exceptions of those
that might be expected with an infection—
white blood cells (WBC), lymphocytes, and
monocytes.
The data showed that on admission 136
patients had a hemoglobin concentration below
the lower limit of the reference range (i.e.,
130 g/L), 79 of whom had a hemoglobin con-
centration of below 100 g/L. Twenty-two
patients had a platelet count below the lower
limit of the reference range (i.e., 150 9 109/L).
The data also showed that six patients had one
or more component of the WBC below the
lower limit of the reference range. Five patients
were highlighted to have low hemoglobin,
white cells, and platelets, suggesting pancy-
topenia at some stage during their admission.
Of these, two patients had potential causes for
this. A 65-year-old man had known follicular
lymphoma and had had a stem cell transplant
prior to admission for the diabetic foot infec-
tion. His baseline values prior to the adminis-
tration of piperacillin/tazobactam were all low,
as were subsequent values at 14-day follow up.
The other patient was a 73-year-old man taking
darbepoetin alfa (Aranesp) for chronic renal
failure. His WBC and hemoglobin were persis-
tently low, although the platelet count was only
down on day 1, 2 and 14 days post termination
of treatment.
The remaining three patients had no clear
cause for their low values. A 68-year-old man
receiving piperacillin/tazobactam for 7 days had
a low hemoglobin concentration throughout
the study period (between 119 g/L day 5 and
89 g/L at 14 days post treatment). However,
both the WBC and the platelets remained
within the reference range for the duration of
administration only to fall below in the 14-day
post treatment reading. A 63-year-old man had
persistently low hemoglobin level (between
124 g/L and 102 g/L) for the duration of his
admission and low WBC on days 1, 2, and 6
(3.8, 3.0, and 3.1 9 109, respectively) and low
platelets on days 2–6 (between 123 9 109/L and
143 9 109/L). An 84-year-old man receiving the
antibiotic for 5 days had a similar pattern of
persistently low hemoglobin with individual
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low values for WBC (3.6 9 109/L) and platelets
(145 9 109/L) on day 3 only.
Renal Function
Mean eGFR fell during the first 48 h following
admission, and then remained broadly
unchanged until day 7. By day 14, however,
eGFR had risen to above admission values.
Serum sodium concentrations rose after the first
24 h following admission to reach a peak by
5 days before falling again by day 14. In con-
trast, mean potassium concentrations rose dur-
ing the first 24 h following admission before
falling by day 2 and then rising by day 7. Mean
urea and creatinine concentrations fell from the
time of admission to 7 days.
DISCUSSION
This study has shown that in a cohort of all
admissions for a severe diabetic foot infection to
a large tertiary specialist care center during a
single calendar year, the use of piperacillin/ta-
zobactam had no adverse effect on any mea-
sured hematological or inflammatory markers.
In addition, the use of piperacillin/tazobactam
led to rapid resolution of abnormal blood
results which were associated with the under-
lying infection triggering the initial admission.
This confirms the antibiotic’s excellent broad-
spectrum cover, suggesting it is an effective and
safe medication for the treatment of diabetes-
related foot infections. Furthermore, these
findings justify the inclusion of piperacillin/ta-
zobactam in specialist diabetic foot formularies
[14].
These data have many strengths. One year of
data was analyzed from a large regional center
for treatment of severe diabetic foot infec-
tions. Patients were successfully followed up for
14 days, which directly addressed the concern
that hematological abnormalities resulting from
piperacillin/tazobactam administration were
time dependent [25] and possible within the
first 15 days [26]. The patients re-
ceived piperacillin/tazobactam for an average of
5.3 days, and no patient exceeded 15 days of
continuous treatment. As well as this, the same
authors [25] suggested that the blood dyscrasias
were dose dependent. Over 85% of the cohort in
the current study received 4.5 g of
piperacillin/tazobactam three times per day; 22
(13%) patients received the antibiotic twice a
day and one patient only having a stat dose.
That this study was carried out in a single cen-
ter, with all of the blood results being available
also increases the validity of the findings,
although we acknowledge that being a single-
center study can also be seen as a limitation.
The format of the study also provides strength.
However, having rapid access to microbiological
advice from the same consultant ensured con-
sistency of care.
However, there are also several limitations. It
is reported that hematological abnormalities,
including pancytopenia, occur very rarely with
the administration of piperacillin/tazobactam.
The incidence has not been determined, with
the manufacturer stating the frequency of this
adverse effect is unknown [15] and the UK Bri-
tish National Formulary suggesting it occurs
very rarely [17]. Evidence suggesting the link is
largely made up from case studies which also
imply that this adverse effect is uncommon
[18–25]. Therefore, with a sample size of 154
patients it may be very difficult to detect this
rare event. A larger potentially multicenter
cohort is required to more accurately determine
a correlation between piperacillin/tazobactam
administration and the development of any
hematological abnormalities.
Fig. 2 Mean concentrations of C-reactive protein over
time
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The present study followed up patients for
14 days post administration of piperacillin/ta-
zobactam. No longer-term follow-up was per-
formed. Evidence suggests that the correlation
is dose and duration dependent [25]. However,
it is possible that hematological abnormalities
associated with the antibiotic occurred after the
follow-up period, although this has not been
reported. It would also be difficult to assess as
blood results are not routinely taken after this
time. However, because the mean length of
administration was less than 6 days, and blood
was taken up to 8 days later, with almost all
normalizing by then, it was felt that the devel-
opment of piperacillin/tazobactam-induced
hematological abnormality beyond that time
would be unlikely.
The results were analyzed as overall means of
each parameter. However, where there were
outliers the individual patient records were
examined to look for any trends in other
hematological abnormalities. None were
identified.
There were several confounding factors that
need to be taken into account, despite no
abnormal blood results being found. These
included patients being on other antibiotics
depending on antimicrobial sensitivities. These
included ciprofloxacin, metronidazole,
trimethoprim, vancomycin, gentamicin, flu-
cloxacillin, and doxycycline. These medications
have the capacity to interfere with hematolog-
ical values [17]. In addition, the local foot for-
mulary suggests co-amoxiclav 625 mg three
times daily after piperacillin/tazobactam treat-
ment [14]. This might have improved the fol-
low-up results. Furthermore, whilst there were
three patients who had a mild degree of pan-
cytopenia during their treatment, we were
unable to account for why they developed it.
Whilst other potential causes of pancytopenia
were sought in all patients—i.e., other medical
conditions or the use of any drugs—by looking
at discharge summaries, these are known to be
inaccurate [28]. It may well be that these
abnormalities were as a result of the
piperacillin/tazobactam treatment. Several
other patients were found to have conditions or
be on medications that may have predisposed
to developing pancytopenia, but all had normal
hematological parameters. These included 16
patients with various conditions known to
cause pancytopenia (hematological malig-
nancy, medication (methotrexate, mycophe-
nolate mofetil, and tacrolimus),
hypothyroidism, liver disease, and renal
failure).
In summary, NICE guidance recommends
broad-spectrum antibiotics in the management
of diabetes-related foot infections [29]. Whilst
piperacillin/tazobactam has been very rarely
associated with the development of hemato-
logical abnormalities, in particular pancytope-
nia, the present study failed to show this. Thus
piperacillin/tazobactam remains an effective
and safe medication for these patients. How-
ever, much larger studies are needed to deter-
mine the incidence of this very rare
complication.
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